AstraZeneca’s lung cancer immunotherapy trial fails to meet primary endpoint
PFS is one of the three primary endpoints in the randomised, open-label, multi-centre, global trial, dubbed MYSTIC, which compared Imfinzi as a monotherapy or in combination with tremelimumab
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.